IMM-124E

4 stories · following the connections

Business

Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

By Nasdaq OMXMay 8, 2018, 1:43 AM UTC

Business

Immuron to Receive $2.16M R&D Tax Concession Refund

By Nasdaq OMXJan 24, 2018, 2:30 PM UTC

Business

Immuron Granted US Patent for NASH Treatment

By Nasdaq OMXNov 15, 2017, 2:00 PM UTC

Business

Immuron Successfully Completes NASH Phase II Clinical Study Milestone

By Nasdaq OMXNov 9, 2017, 2:01 PM UTC